|Mr. Gene G. Kinney||Pres, CEO & Director||901.12k||N/A||1969|
|Mr. Tran B. Nguyen M.B.A.||CFO & COO||679.37k||N/A||1974|
|Mr. Michael J. Malecek||Chief Legal Officer & Company Sec.||588.25k||N/A||1966|
|Ms. Carol D. Karp||Chief Regulatory Officer||624.39k||N/A||1953|
|Mr. Brandon S. Smith||Chief Bus. Officer||580.92k||N/A||1975|
|Ms. Karin L. Walker CPA||Chief Accounting Officer & Controller||N/A||N/A||1963|
|Dr. Wagner M. Zago||Chief Scientific Officer||N/A||N/A||1973|
|Ms. Jennifer Zibuda||Director of Investor Relations & Communication||N/A||N/A||N/A|
|Ellen Rose||Head of Communications||N/A||N/A||N/A|
|Dr. Radhika Tripuraneni M.P.H., M.D.||Chief Devel. Officer||N/A||N/A||1980|
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc’s ISS Governance QualityScore as of April 30, 2021 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 5; Compensation: 8.